Celldex Therapeutics, Inc. (CLDX) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity cushion ⢠Deep losses ⢠High burn CLDX has a strong liquidity buffer and minimal leverage, but severe losses, heavy cash burn, and negligible revenue make the investment case fundamentally risky.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Failed rebounds ⢠Weak support Support Level: $28.90 Resistance Level: $30.50â$31.00 CLDX remains in a clear downtrend over the last month, having lost the $30.50â$31.00 resistance zone and broken below $28.90, with only a short-term bounce likely if it reclaims $29.93â$30.14.
Sentiment & News
Key News Insights: ⢠Wider Q1 loss ⢠CSU milestone ⢠Strong cash runway Celldex posted a wider-than-expected Q1 loss, but early CSU Phase 3 completion, upcoming data readout, and a strong cash position support its immunology pipeline outlook.
AI Summary
CLDX should be viewed primarily as a late-stage catalyst play rather than a near-term earnings story: its strong cash position buys time for barzolvolimab's CSU readout, but the broken chart and heavy dependence on one binary data event mean the stock likely stays fragile until Phase 3 proof is delivered.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |